Levosimendan Accord (Levosimendan)

Levosimendan is used in the management of heart failure, particularly acute decompensated heart failure.

• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Severe left ventricular dysfunction: provides inotropic support when conventional therapy is insufficient.
• Post‑cardiac surgery low‑output syndrome: helps restore adequate systemic perfusion during the early postoperative period.

• Levosimendan increases cardiac contractility by binding to troponin C and sensitising it to calcium, thereby enhancing the force of myocardial contraction without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload, which together improve cardiac performance.

Levosimendan may be associated with several adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Hypotension: reduction in blood pressure, especially after rapid infusion.
• Nausea or vomiting: gastrointestinal discomfort during or after administration.
• Tachycardia: increased heart rate, usually dose‑related.
• Dizziness: sensation of light‑headedness, often linked to blood pressure changes.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening irregular heart rhythms.
• Myocardial ischemia: chest pain due to reduced coronary blood flow.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan should be used with careful clinical monitoring.

• Blood pressure monitoring: observe for hypotension during infusion.
• Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
• Renal function assessment: adjust therapy in severe renal impairment.
• Hepatic impairment caution: consider reduced clearance in liver disease.
• Contraindication in severe hypotension: avoid use when systolic pressure is markedly low.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
• Strong CYP450 inhibitors (e.g., ketoconazole): can increase plasma concentrations.
• Potassium‑channel blockers: additive effects on vascular tone.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate electrolyte shifts and hypotension.
• Beta‑blockers: may blunt the inotropic response.
• ACE inhibitors or ARBs: combined effect on blood pressure needs observation.